Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol

• Georg Griesinger ,

  * E-mail: georg.griesinger@uni-luebeck.de

  Affiliation Department of Reproductive Medicine and Gynecological Endocrinology, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany

  ⨯
• Pierre J. M. Verweij,

  Affiliation MSD BV, Oss, The Netherlands

  ⨯
• Davis Gates,

  Affiliation Merck & Co., Inc., Kenilworth, NJ, United States of America

  ⨯
• Paul Devroey,

  Affiliation Center for Reproductive Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium

  ⨯
• Keith Gordon,

  Affiliation Merck & Co., Inc., Kenilworth, NJ, United States of America

  ⨯
• Barbara J. Stegmann,

  Affiliation Merck & Co., Inc., Kenilworth, NJ, United States of America

  ⨯
• Basil C. Tarlatzis

  Affiliation 1st Department of Obstetrics and Gynecology, Papageorgiou Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

  ⨯